Followers | 80 |
Posts | 3,532 |
Boards Moderated | 0 |
Alias Born | 06/04/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Story going viral Sen. Paul and Franken to end MJ Prohibition
http://www.gq.com/story/al-franken-and-rand-paul-join-forces-to-protect-medical-marijuana-from-jeff-sessions
NEWS USA senators introduce bill to end federal prohibition on medical marijuana
Http://www.marketwatch.com/story/senate-introduces-bill-to-end-federal-medical-marijuana-prohibition-2017-06-15
On the PRs ..If you read the past releases it indicates the approx timelines for certain events
The company has stated many times Q2/Q3 market readiness announcement
Appears they are finally ready..
We are all here for a breakthrough protected product to hit the shelves that will do wonders for people suffering with psoriasis I speak to people all the time that have this and suffer from this disease
and the medications they have are basically useless expensive and don't fix the problem and carry harmful side effects
OWCP has indicated this is a potential breakthrough product
I can't wait for it to hit the shelves
it's a multi billion dollar industry worldwide
Just imagine even 1 or 2% of this market is massive
Big UPDATE next week ..was told by IR
and Market Readiness announcement to follow as previously announced and even more including new CFO news per 8K - July 1st !
Wonder what the more is ?
When you have the number one medical cannabis doctor in Israel possibly on the planet anything is possible
Buy the dips
Everyone will be happy.
Registrant anticipates appointing a new CFO on or about July 1, 2017, until which date Mr. Mordechai Bignitz, who is the Registrant's CEO and Chairman and is also a CPA and accountant by education and training, will serve as Interim CFO.
#2 on Apple Downloads
Wow !!
Is that true ?
I downloaded the game it's FUN
And graphics are cool
To be able to win REAL CASH prizes are HUGE
Everyone should download it !!!
Freeze Tag CEO Video
https://vimeo.com/91665602
CBD Products Market Becoming Hottest Segment of Cannabis Industry as Demand Continues to ExplodeFont
8:30 AM ET 6/13/17 | Dow Jones
MarketNewsUpdates.com News Commentary
PALM BEACH, Florida, June 13, 2017 /PRNewswire/ --
As the demand for CBD-based products explodes in the U.S. and continues to thrive across the globe, Cannabis-based companies race to develop and introduce the newest and higher quality products to capitalize on the momentum. Much like most of the cannabis and legal medical marijuana market, vendors and manufacturers focus on delivering a high degree of quality infused in their CBD-based products. Cannabis companies in the news or active in the markets this week include: Earth Science Tech, Inc. (OTC: ETST), GW Pharmaceuticals plc (NASDAQ: GWPH), Canopy Growth Corporation (TSX: WEED.TO) (OTC: TWMJF), OWC Pharmaceutical Research Corp (OTC: OWCP) and MassRoots, Inc. (OTC: MSRT)
Earth Science Tech, Inc. (OTC: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices is pleased to announce its new wholly-owned subsidiary KannaBidioid Inc. to manufacture and distribute vapes/e-liquids and gummy edibles to target vape/smoke shops. After a successful May 2017, launch of ETST's new products: Strawberry Orange Blossom CBD oil, CBD Organic Chocolate line, and Pet CBD oil, ETST's management team came across an opportunity to step into the recreational vape/smoke space. Earth Science is excited to announce it will begin to formulate, produce and sell Kanna-infused cannabidiol (CBD) based e-liquids and gummy edibles, hence KannaBidioid, Inc. (KBD). Read this and more news for ETST at http://www.marketnewsupdates.com/news/etst.html
Kanna (Sceletium tortuosum) is known to elevate mood, decrease anxiety, stress and tension, and suppress the appetite. In moderate doses, it induces euphoria and acts as a powerful stimulant, but can actually have a sedative effect in larger doses. "Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus, and help with nicotine addiction based on their properties," stated Dr. Michel Aube, ETST's CEO & CSO. Dr. Aube elaborates with, "CBD is a strong antioxidant that enhances well-being, among other properties, by reducing the oxidative stress produced by the human brain through its elevated metabolic activity. While Kanna might also have anxiolytic potential, as it modulates the biological activity of serotonin, the two together will significantly reduce anxiety as the Hemp Oil will create better physiological conditions for the biological activity of the Kanna extract. All together, the full spectrum of the Hemp Oil and full spectrum of the Kanna plant have the potential to better regulate the activity of serotonin, giving a more powerful sensation of satisfaction than any other plant extract used alone.
In other industry related developments and market activity:
GW Pharmaceuticals plc (NASDAQ: GWPH) closed up on Monday afternoon with over 280,000 shares traded on the day. The company recently announced it will present at the Goldman Sachs 38th Annual Global Healthcare Conference on this Wednesday, 14 June at 11:20 a.m. (PDT) at the Terranea Resort, Rancho Palos Verdes, CA. A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at http://www.gwpharm.com. A replay will be available soon after the live presentation.
Canopy Growth Corporation (TSX: WEED.TO) (OTC: TWMJF) closed up 2.55% at $8.04 on the TSX and up over 3% at $6.0356 on the OTC Market on Monday. Canopy Growth Corporation this month welcomed PUF Ventures Inc. (CSE: PUF), a London, Ontario-based late-stage ACMPR applicant, to the Tweed Main Street curated CraftGrow line. Pending a license to cultivate and sell cannabis products, PUF will become the fourth company to join CraftGrow. The program accelerates speed to market for newly licensed producers and provides brand and product exposure by selling partner products via http://www.tweedmainstreet.com to the market's largest group of actively registered customers.
OWC Pharmaceutical Research Corp (OTCQB: OWCP) closed up 3.79% on Monday with just shy of 700,000 shares traded by the market close. OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.
MassRoots, Inc. (OTCQB: MSRT) recently announced strategic investment in High Times Holding Corporation, "High Times", the leading voice of the Cannabis Industry, in February 2017. As disclosed in MassRoots' Quarterly Report on Form 10-Q filed on May 22, 2017, MassRoots has made a strategic equity investment in High Times Holdings Corporation. Over the past forty years, High Times has built an iconic brand and business with innovative and forward-minded strategy at the front of the cannabis legalization movement. High Times maintains a portfolio of high-quality brands, including the Cannabis Cup and High Times Magazine, and a reputation for being at the leading edge of industry trends, information and news.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Earth Science Tech, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information:
Media Contact email: info@marketnewsupdates.com
+1(561)325-8757
SOURCE MarketNewsUpdates.com
> Dow Jones Newswires
June 13, 2017 08:30 ET (12:30 GMT)
BitCoin solves Legal Marijuana Federal Banking Problem
https://apple.news/AMop2RLMjOXWVy0qiqMeqmQ
Cannabis is in your DNA
The future is bright
Don't be confused management is incentivized by the stock and the stock price 100%
OWC soon will have a breakthrough protected product to hit the market with unparalleled research
It's what we're all here for
Can't wait to hear where it starts selling first
Israel / Europe / USA / Canada ?
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12117417
The Registrant has determined to evaluate the potential benefits of cross listing its shares of common stock, currently subject to quotation on the OTCQB: OWCP, for listing on a Canadian stock exchange, such as the Toronto Stock Exchange, among others.
We believe that cross listing may improve the Registrant's access to capital and liquidity. To this end, the Registrant has agreed to engage a major national Canadian law firm with specific expertise in venture capital markets to assist us in achieving a listing on a Canadian exchange.
its their consultant not the company Directly
Buy the Dips also OWCPharma1@Gmail.com
https://www.intivabiopharma.com/videos
UPDATED JUNE 9th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
Buy the Dips !
Buy the dips
Buy the dips..
UPDATED JUNE 7th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED JUNE 4th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED JUNE 2 $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
UPDATED JUNE 2nd $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
RSI has come way down
June will be big
These guys are just the middleman to bridge together joining all the different European countries to sell OWC products
Once the product is officially market ready (soon per the co. )
I think you'll see these guys in action
Lots more to come
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
UPDATED May30th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/ybdgu2l2
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
April 5th 2017 - OWC Pharmaceutical Research Corp Releases Promising Preliminary Results [70%] From Efficacy Tests of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html
OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku
OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings
?$OWCP & German Based medic Innovation Experts ?
?to launch OWCP's cannabinoid-based topical psoriasis cream in Europe?
?https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-enters-110000236.html
You cannot have a sales contract when your product is not quite ready for sales
however [ they say ] it will be ready soon Q2/Q3
Lets Stay Tuned
IMO watch them sign up every country in Europe !!!
reminder its a BIG world out there !!!
its for Tomorrows release and yes its already May 31st in Israel
YUP !! This is just THE BEGINNING...
we are still just in May
follow OWCP on Twitter
https://twitter.com/OWCPharma
$OWCP signs agreement w/ Germany Based mediq Innovation Experts for Cannabis Based Psoriasis Cream to GERMAN Market
http://tinyurl.com/yal5pcac
$OWCP NEWS ~~~ Date: May 31, 2017
follow OWCP on Twitter
https://twitter.com/OWCPharma
OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts
The Initial Objective of the Collaboration is the Introduction of OWC's Active Cannabinoid-Based Topical Psoriasis Cream to the German Market
PETACH TIKVA, Israel, May 31, 2017 - OWC Pharmaceutical Research Corp. (OTC: OWCP) and mediq Innovation Partners (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market.
Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets. mediq's objectives for OWCP will consist of both scientific collaboration and most importantly the development of a commercial market for OWCP's proprietary, active cannabinoid-based topical psoriasis cream in Germany.
Commenting on the collaboration with OWCP, Jan Wende, managing director of mediq stated, "We are looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany.
Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP's proprietary cannabinoid-based topical psoriasis cream is the right product at the right time. Furthermore, Germany is the largest European healthcare market and therefore offers the perfect platform to gain local evidence and roll out the concept into other European countries. Our initial focus for OWCP is on the German market, however we're excited about the long-term opportunities throughout Europe, a market with a population of over 740 million."
Alon Sinai, managing director of OWCP's wholly-owned, Israel-based subsidiary, One World Cannabis, also commented on the collaboration with mediq, "The German market is a great opportunity for OWCP.
Germany, with its population of over 81 million, and a gross domestic product of over US$3.36 trillion is the largest economy in Europe. Also, potentially beneficial to OWCP is Germany's recent medical cannabis legislation, which currently limits the usage of smokable-products, and which also provides for reimbursement for medical cannabis by the country's healthcare system. mediq is a great partner for OWCP, and we're looking forward to the prospects of a long-term and mutually relationship with the company both regarding the introduction of OWCP's cannabinoid-based psoriasis cream in the German marketplace, but also for the prospects for scientific collaboration in the country."
About OWCP's Active Cannabinoid-Based Psoriasis Cream
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States.
OWCP has developed a proprietary active cannabinoid-based topical cream for psoriasis management, with the objective of reducing the skin dryness of patients suffering from the disease. The Company previously reported trial results that concluded that after application of the Company's active cannabinoid-based topical cream formulation, there was up to a 70% improvement in a variety of inflammation markers directly associated with psoriasis.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/
About mediq Innovation Experts
Frankfurt, Germany-based mediq Innovation Experts (mediq) has vast experience in the European healthcare market. Over the past ten years mediqhas successfully introduced disruptive technologies and services throughout the continent. The company's deep understanding of the market dynamics, regulatory, and reimbursement structures is a benefit in enabling international healthcare companies to develop European implementation strategies.
mediq's core capabilities include market assessment, strategy development, clinical validation, scientific marketing strategy, and marketing channel development. For more information visit http://innovationexperts.de.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
Mordechai Bignitz Chairman and CEO
Email: mordechai.bignitz@owcpharma.com
Tel: +972-(0)3-770-8526